Document is current
Any future updates will be listed below
-
Authors
Adegbite, Bayode R.
Edoa, Jean R.
Honkpehedji, Yabo J.
Zinsou, Frejus J.
Dejon-Agobe, Jean C.
Mbong-Ngwese, Mirabeau
Lotola-Mougueni, Fabrice
Koehne, Erik
Lalremruata, Albert
Kreidenweiss, Andrea
Nguyen, The T.
Kun, Jutta
Agnandji, Selidji T.
Lell, Bertrand
Safiou, Abdou R.
Obone Atome, Fridia A.
Mombo-Ngoma, Ghyslain
Ramharter, Michael
Velavan, Thirumalaisamy P.
Mordmüller, Benjamin
Kremsner, Peter G.
Adegnika, Ayola A. https://orcid.org/0000-0003-3197-5946
-
Clinical Trials BETA
Clinical trials referenced in this document:
actrn12616001600437 at Australian New Zealand Clinical Trials RegistryDocuments that mention this clinical trial
Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial
https://doi.org/10.1186/s12936-019-3015-4
-
Funding
Funding for this research was provided by:
WHO (TES 2017_1071_001)
Ministry of Health of Gabon
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 20 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: The National Ethics Committee (CNE) of Gabon (PRO 0017/2017/SG/CNE) and the institutional ethic committee of CERMEL (CEI 004/2017) approved the study protocol as well as the WHO Ethical review committee. The study protocol was explained to the parent or legal guardian and written informed consent was obtained before participant inclusion.
: Not applicable.
: The authors declare that they have no competing interests.
